Semax occupies unusual territory. In Russia it has a history of clinical use in cerebrovascular medicine. In English-language consumer markets it is sold as a nootropic for focus and productivity.
Those two framings imply very different evidence bases, and only one of them was in front of the FDA.
The basics
| Field | Detail |
|---|---|
| Structure | Heptapeptide; an ACTH(4–7) fragment analog with a Pro-Gly-Pro extension |
| Origin | Developed in Russia; a history of clinical use there in cerebrovascular indications |
| Reviewed for | Cerebral ischemia, migraine, trigeminal neuralgia |
| PCAC vote | 8 yes, 5 no, 1 abstention — recommended |
| FDA staff position | Recommended against inclusion |
| Current status | Not eligible for compounding |
The Pro-Gly-Pro extension is the design feature worth noting. Short peptides are rapidly degraded by peptidases; that terminal tripeptide was added to slow degradation and extend the molecule's working lifetime. It is a deliberate stability solution, not an accident of structure.
What it was reviewed for, and what it is sold for
Cerebral ischemia. Migraine. Trigeminal neuralgia. Three clinical neurology indications, all involving identifiable pathology in patients under medical care.
None of them is cognitive enhancement in healthy adults.
That distinction matters more than it might appear, because the two questions have different evidence requirements and often different answers. A compound that helps restore function after ischemic injury is being asked to do something quite different from improving concentration in someone whose brain is working normally. Neuroprotective or restorative effects in damaged tissue do not generalize to enhancement in healthy tissue, and the history of nootropics is largely a history of that inference failing.
The clean version
Semax's most defensible literature concerns clinical neurology populations. Its most common marketing concerns healthy people wanting to focus. The evidence supporting the first does not transfer to the second, and the second has very little supporting it directly.
On the Russian clinical history
Semax has been used clinically in Russia, and that history is real. It is also the basis for the “decades of clinical use” framing that appears in marketing.
Two things are worth holding simultaneously. First, regulatory approval in another jurisdiction is meaningful evidence that a body reviewed something and reached a conclusion. Second, approval standards, trial design requirements and post-market surveillance differ substantially between regulatory systems, so approval elsewhere is not equivalent to FDA approval and does not substitute for it.
Notably, supporters at the July meeting made a version of this argument generally — that a long history of use by licensed practitioners weighs in favor of inclusion. FDA scientists were unpersuaded across all seven compounds, citing insufficient safety and effectiveness data and inadequate characterization.
Delivery route
Semax is commonly encountered as an intranasal preparation. Intranasal delivery is a genuine strategy for peptides — it avoids first-pass metabolism and has been explored for nose-to-brain transport — but the efficiency of that route is variable and formulation-dependent.
Route is also a live regulatory variable in this area generally. GHK-Cu's status differs by route, with non-injectable preparations treated differently from injectable ones. Assuming that a status determination covers every delivery format is a mistake.
Where it stands
Recommended 8–5–1, against FDA staff advice, with no rulemaking initiated. Semax is not an approved drug in the United States and is not eligible for 503A compounding.
Expect the vote to be marketed as validation of cognitive claims it has nothing to do with.
Common questions
It has a history of clinical use in Russia in cerebrovascular indications. It is not approved in the United States, and approval standards differ substantially between regulatory systems.
That is the common marketing claim and it is the least supported. The more defensible literature concerns clinical neurology populations. Effects in damaged tissue do not reliably generalize to enhancement in healthy tissue.
Cerebral ischemia, migraine and trigeminal neuralgia — three clinical indications, none of them cognitive enhancement.
To slow enzymatic degradation. Short peptides are broken down quickly by peptidases, and the terminal extension is a deliberate stability modification.
Intranasal administration is a legitimate strategy for peptides and avoids first-pass metabolism, but delivery efficiency is variable and formulation-dependent. It should not be assumed equivalent to other routes.
Sources
- US Food and Drug Administration. PCAC meeting, July 23–24, 2026. Meeting docket FDA-2026-N-2979; bulk substances docket FDA-2025-N-6895. fda.gov
- McDermott Will & Schulte. “Bulk-list bound? PCAC backs majority of peptides in two-day public meeting.” July 27, 2026.
- Orrick. “FDA Peptide Compounding Vote: What to Watch at the July PCAC Meeting.” July 2026.
- Sheppard Mullin. “Compounded Peptides on the Loose: What the Recent PCAC Meeting Means for Industry.” August 2026.
- Fierce Pharma. “Peptide adcomm Day 2: Emideltide voted down in panel’s 1st pushback.” July 2026.